For research use only. Not for therapeutic Use.
KYN-101 is a potent, selective and orally active AHR inhibitor. KYN-101 decreases the CYP1A1 mRNA expression. KYN-101 shows anti-cancer activity[1].
KYN-101 (0.5, 1 µM; 24 h) decreases the CYP1A1 mRNA expression in IDOhigh samples[1].
KYN-101 (10 mg/kg; p.o.; daily for 12 days) shows anti-cancer activity in mice[1].
| Catalog Number | I041319 |
| CAS Number | 2247950-73-6 |
| Synonyms | 5-(5-fluoropyridin-3-yl)-N-[2-(1H-indol-3-yl)ethyl]-3-methylpyrazolo[1,5-a]pyrimidin-7-amine |
| Molecular Formula | C22H19FN6 |
| Purity | ≥95% |
| InChI | InChI=1S/C22H19FN6/c1-14-10-27-29-21(9-20(28-22(14)29)16-8-17(23)13-24-11-16)25-7-6-15-12-26-19-5-3-2-4-18(15)19/h2-5,8-13,25-26H,6-7H2,1H3 |
| InChIKey | XIBYMKUWLQLNLC-UHFFFAOYSA-N |
| SMILES | CC1=C2N=C(C=C(N2N=C1)NCCC3=CNC4=CC=CC=C43)C5=CC(=CN=C5)F |
| Reference | [1]. Campesato LF, et al. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nat Commun. 2020 Aug 11;11(1):4011. |
